体内
纳米载体
癌症研究
厌氧糖酵解
糖酵解
癌细胞
重编程
药物输送
药理学
细胞
材料科学
化学
癌症
纳米技术
生物化学
生物
新陈代谢
生物技术
遗传学
作者
Qiangqiang Zhao,Jian Li,Bin Wu,Yilun Shang,Xueyuan Huang,Hang Dong,Haiting Liu,Wansong Chen,Rong Gui,Xinmin Nie
标识
DOI:10.1021/acsami.0c05763
摘要
Toxicity and drug resistance caused by chemotherapeutic drugs have become bottlenecks in treating tumors. The delivery of anticancer drugs based on nanocarriers is regarded as an ideal way to solve the aforementioned problems. In this study, a new antilymphoma nanodrug CD20 aptamer-RBCm@Ag-MOFs/PFK15 (A-RAMP) is designed and constructed, and it consists of two parts: (1) metal–organic frameworks Ag-MOFs (AM) loaded with tumor aerobic glycolysis inhibitor PFK15 (P), forming a core part (AMP); (2) targeted molecule CD20 aptamer (A) is inserted into the red blood cell membrane (RBCm) to form the shell part (A-R). A-RAMP under the guidance of CD20 aptamer actively targets B-cell lymphoma both in vitro and in vivo. As a result, A-RAMP not only significantly inhibits the effect on tumor growth but also shows no obvious side effects on the treated nude mice, indicating that A-RAMP can accurately target tumor cells, reprogram aerobic glycolysis, and exert synergistic antitumor effect by Ag+ and PFK 15. Furthermore, the antitumor mechanism of A-RAMP in vivo by apoptotic pathway and targeting metabonomics are explored. These results suggest that A-RAMP has a promising application prospect as an smart, safe, effective, and synergistic antilymphoma agent.
科研通智能强力驱动
Strongly Powered by AbleSci AI